<DOC>
	<DOCNO>NCT00876616</DOCNO>
	<brief_summary>The purpose study assess efficacy safety multi-target therapy treatment class Ⅲ , Ⅳ , Ⅴ , Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis .</brief_summary>
	<brief_title>Assess Efficacy Safety Multi-target Therapy Lupus Nephritis</brief_title>
	<detailed_description>1 . To assess efficacy FK506 combine MMF v intravenous cyclophosphamide ( CTX ) pulse treatment class Ⅲ , Ⅳ , Ⅴ , Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis ( LN ) . 2 . To investigate safety tolerability FK506 combine MMF v intravenous CTX pulse treatment class Ⅲ , Ⅳ , Ⅴ , Ⅲ+Ⅴand Ⅳ+Ⅴ LN .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Written inform consent subject guardian 2 . 18 65 year age ( inclusive 18 65 ) , male female 3 . Diagnosis SLE accord American College Rheumatology criterion ( 1997 ) 4 . Diagnosis Class Ⅲ , Ⅳ , Ⅴ , Ⅲ+Ⅴand Ⅳ+ⅤLN accord ISN/RPS 2003 classification light , immunofluorescence , electron microscopy within 6 month enrollment 5 . Pathologic chronic index ( CI ) ≤3 ' without thrombotic microangiopathy ( TMA ) 6 . SLE Disease Activity Index ( DAI ) &gt; 10 ' 7 . Proteinuria ≥1.5g/d，with without active urinary sediment 8 . Serum creatinine ( Scr ) ≤3.0mg/dl ( 265.2 mol/L ) 1 . Previous treatment MMF , CTX , tacrolimus , Cyclosporin A ( CsA ) , large dos immunoglobulin methylprednisolone ( MP ) , plasmapheresis renal replacement therapy within past 12 week . Oral glucocorticoid , azathioprine , intravenous MP ( ≤80mg/d ) ， shorttime CsA ( &lt; 2 week ) leflunomide ( &lt; 4 week ) allow 2 . ALT AST increase twice upper limit normal range 3 . Hyperglycemia define fast blood glucose level ≥7.0 mmol/L and/or postprandial blood sugar level &gt; 11.1 mmol/L 4 . Known hypersensitivity contraindication component MMF , tacrolimus , CTX glucocorticoids 5 . History present illness : 1. active HBV infection ( HBsAg , HBeAg antiHBc positive HBsAg , anti HBe antiHBc positive ) , HCV infection , pulmonary tuberculosis , cytomegalovirus ( CMV ) infection ( defined CMVIgM positive CMVDNA positive ) , fungal infection HIV infection , within 3 month enrollment 2. nonhealed active peptic ulcer within 3 month enrollment 3. drug drinking abuse 4. malnutrition ( BMI &lt; 18.5kg/m2 ) body weight &lt; 50Kg 6 . Other active disease , : 1. severe cardiovascular disease 2. chronic obstructive pulmonary disease ( COPD ) asthma require oral glucocorticoid 3. marrow depression due SLE activation : white blood cell count &lt; 3000/mm3 neutrophil count &lt; 1300/mm3 platelet count &lt; 50000/mm3 7 . Severe infection need antibiotic therapy 8 . Female patient pregnant/breastfeeding patient ( gender ) refuse contraception 9 . Lifethreatening complication large hydropericardium , pneumohemorrhagia , lupus encephalopathy severe pulmonary hypertension patient need MP pulse ( &gt; 0.5g/d ) treatment aggravation SLE 10 . Known noncompliance violation protocol base investigator 's judgement 11 . Patient participate investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>lupus nephritis ; multi-target therapy ; MMF ; FK506</keyword>
</DOC>